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Our aim was to compare the predictive accuracy of 4 different medial temporal lobe measurements for
Alzheimer’s disease (AD) in subjects with mild cognitive impairment (MCI). Manual hippocampal
measurement, automated atlas-based hippocampal measurement, a visual rating scale (MTA-score), and
lateral ventricle measurement were compared. Predictive accuracy for AD 2 years after baseline was
assessed by receiver operating characteristics analyses with area under the curve as outcome. Annual
cognitive decline was assessed by slope analyses up to 5 years after baseline. Correlations with biomarkers
in cerebrospinal ﬂuid (CSF) were investigated. Subjects with MCI were selected from the Development of
Screening Guidelines and Clinical Criteria for Predementia AD (DESCRIPA)multicenter study (n¼ 156) and
the single-centerVUmedical center (n¼172). At follow-up, areaunder the curvewashighest for automated
atlas-based hippocampal measurement (0.71) and manual hippocampal measurement (0.71), and lower
for MTA-score (0.65) and lateral ventricle (0.60). Slope analysis yielded similar results. Hippocampal
measurements correlated with CSF total tau and phosphorylated tau, not with beta-amyloid 1e42. MTA-
score and lateral ventricle volume correlated with CSF beta-amyloid 1e42. We can conclude that volu-
metric hippocampal measurements are the best predictors of AD conversion in subjects with MCI.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Alzheimer’s disease (AD) is the leading cause of dementia in the
elderly, affecting more than 27 million people worldwide. Earlyiatry and Neuropsychology,
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evier OA license.detection of AD might prevent irreversible damage by enabling
preventative treatment (Masters and Beyreuther, 2006; Vellas et al.,
2007). A primary focus of research in AD is identifying which
biomarkers are clinically useful for the early diagnosis of AD.
Medial temporal lobe (MTL) atrophy as assessed using structural
magnetic resonance imaging (MRI) has proven to be an effective
clinical aid in the early diagnosis of AD (Visser et al., 2002a), and this
method predicts AD in subjects with mild cognitive impairment
(MCI) (DeCarli et al., 2007; Rusinek et al., 2004; Schoonenboom
L. Clerx et al. / Neurobiology of Aging 34 (2013) 2003e20132004et al., 2008; Visser et al., 1999, 2002a). There are several ways to
determine the degree of MTL atrophy in the brain including manual
delineation, (semi-) automated techniques tomeasure hippocampal
volume, qualitative ratings of MTL atrophy (MTA-score), and
assessment of lateral ventricular volume (Aljabar et al., 2009;
Apostolova et al., 2006; Chou et al., 2010; Echávarri et al., 2011; Jack
et al., 2004;McHugh et al., 2007; Nestor et al., 2008; Scheltens et al.,
1992; Varela-Nallar et al., 2010; Wolz et al., 2010a, 2010b). Each
of these methods has its strengths and limitations.
Manual volumetry is considered the gold standard (Barnes et al.,
2009; Boccardi et al., 2011; van de Pol et al., 2007b) but is time-
consuming, which limits routine clinical or large-scale research
use. Automatedmeasurements are quick and widely applicable, but
might be susceptible to scanner and scan protocol variability.
Volumetric measurements of the lateral ventricle require
a minimum of rater time with robust automatic segmentations but
show a lot of variability and asymmetry between subjects (Nestor
et al., 2008). Qualitative ratings are quick to perform but sensitive
to interrater variability and show lower accuracy rates compared
with volumetric analysis (DeCarli et al., 1990; Galton et al., 2001).
Visual rating scales are furthermore insensitive to detect atrophy
progression over time (Ridha et al., 2007).
A number of studies have examined differences between various
techniques to measure atrophy of the MTL, mostly comparing
manual with automated hippocampal volumetry (Lehmann et al.,
2010; Sanchez-Benavides et al., 2010b; Shen et al., 2010) or volu-
metric hippocampal measurements to a visual rating scale (Ridha
et al., 2007; Scheltens et al., 1992; Urs et al., 2009; Wahlund et al.,
2000; Westman et al., 2011). These studies typically evaluate the
diagnostic accuracy of different MRI techniques by comparing AD
patients with healthy control subjects. Most studies found that
manual hippocampal measurement and automated hippocampal
segmentation results were similar (Hsu et al., 2002; Lehmann et al.,
2010). However, the performance of automated techniques might
be less precise when applied in AD patients suffering from mod-
erate to severe brain atrophy and/or white matter hyperintens-
ities which might lead to false allocations of gray matter, white
matter, or cerebrospinal ﬂuid (CSF) (Carmichael et al., 2005; Levy-
Cooperman et al., 2008; Sanchez-Benavides et al., 2010a). One
study reported that visual rating of MTL atrophy is a quick and
clinically useful technique for differentiating AD from control sub-
jects and is quicker and more accurate than volumetry (Wahlund
et al., 2000).
To our knowledge, no study has compared the diagnostic
performance of manual and atlas-based hippocampal segmenta-
tion, lateral ventricle volume, and a qualitative rating. Moreover, no
comparative studies have been performed on the predictive accu-
racy of these different methods to predict AD in subjects with MCI,
their relation with CSF biomarkers of AD, and the effect of multi-
center settings on diagnostic performance.
The aim of the present longitudinal study was to compare the
predictive accuracy of 4 different MTL measurements for the
progression to AD-type dementia in patients with MCI over a 2-
year follow-up period. Atrophy of the MTL was assessed using
manual measurement of the hippocampus, automatically mea-
sured hippocampal volume based on atlas registration (learning
embeddings for atlas propagation; LEAP), volumetric measurement
of the expansion of the lateral ventricle, and a largely used quali-
tative rating scale. Because subjects might convert at a later point in
time, slope analyses were additionally performed with annual
cognitive decline up to 5 years as an outcome measure. The
correlation of MTL measures with AD biomarkers in CSF was also
investigated and the predictive accuracy was tested in a multi-
center study with different scan protocols and in a single-center
study.2. Materials and methods
2.1. Subjects
We selected participants with MCI from the Development of
Screening Guidelines and Clinical Criteria for Predementia AD
(DESCRIPA) study and the Alzheimer Center of the VU University
Medical center (VUmc) in Amsterdam. DESCRIPA is a multicenter
prospective cohort study from the European Alzheimer’s Disease
Consortium aimed at developing clinical criteria and screening
guidelines for predementia AD (Visser et al., 2008). For this study
participants were selected from 9 of the 20 participating centers
where MRI scanning was performed as part of clinical practice or as
research protocol. The VUmc cohort in the present study included
the VUmc subjects enrolled in the DESCRIPA study and an addi-
tional sample of subjects that were seen outside the DESCRIPA
inclusion period (Supplementary Appendix 1).
Inclusion criteria for both cohorts were: age 54 years or older,
diagnosis of MCI, and availability of results for each MRI measure
and outcome at follow-up. Exclusion criteria were diagnosis of
dementia at baseline or any somatic, psychiatric, or neurological
disorder (e.g., epilepsy) that might have caused the cognitive
impairment (Visser et al., 2008). At baseline, scans were available
for 456 subjects. Visually rated MTL atrophy was available for all
subjects. Of these, 54 had no follow-up data and were excluded. Of
the remaining 402 subjects, scans were not available in digital
format for 21 subjects. Of the remaining 381 scans, manual
segmentation of the hippocampus could be performed on 341 scans
(reasons missing: technical problem in volumetric measurement
[n ¼ 5], technical problem in automated intracranial volume esti-
mation [n ¼ 25], and logistical [n ¼ 10]), LEAP-based volumetry on
357 scans (reasons missing: technical problem in volumetric
measurement [n ¼ 11] and logistical [n ¼ 13]), and lateral ventricle
volumetry on 335 scans (reasons missing: technical problem in
volumetric measurement [n ¼ 37], and logistical [n ¼ 9]). Data for
all 4 medial temporal lobe measurements were available for 328
subjects; 156 from DESCRIPA and 172 from VUmc. There were no
differences between included and excluded subjects with respect to
age, sex, educational level, and cognitive test results.
2.2. Clinical and cognitive assessment
All participants underwent a standard diagnostic workup, in-
cluding clinical history,medical andneurological examination, clinical
chemistry, functional evaluation using the Clinical Dementia Rating
scale (Morris,1993), theMini-Mental State Examination (MMSE), and
rating scales for depression and neuropsychiatric symptoms. A neu-
ropsychological battery was performed to evaluate performance in
several cognitive domains. In each center a primary test for verbal
memory, language, attention, executive functioning, and visuocon-
structionwas chosen thatwas identical or similar to tests used inother
centers (Visser et al., 2008). Raw scores on neuropsychological tests
were corrected for age, education, and sex, in accordance with locally
collected or published normative data and expressed as z-scores,
which were used for further analysis. Baseline diagnosis of MCI was
made according to the criteria of Petersen and colleagues (Petersen,
2004; Petersen et al., 1999). Subjects with a z-score <-1.5 SD on any
of the following tests: the learningmeasure or delayed recall of aword
list learning test or equivalentmemory test, the TrailMaking Test part
A, Trail Making Test part B, verbal ﬂuency, Rey ﬁgure copy test or an
equivalent testwere deﬁned as havingMCI (referenceVos). (Vos et al.,
2012). We calculated a composite score as the average z-score of the
6 tests if scores were available for at least 3 tests (Visser et al., 2009).
Follow-up was conducted annually for up to 5 years. The
primary outcome measure was conversion to AD-type dementia
L. Clerx et al. / Neurobiology of Aging 34 (2013) 2003e2013 2005after 2 years. AD diagnosis was made according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition (American
Psychiatric Association, 1994) and National Institute of Neurolog-
ical and Communicative Diseases and Stroke/Alzheimer’s Disease
and Related Disorders Association criteria (McKhann et al., 1984).
Secondary outcomemeasures were annual cognitive decline on the
MMSE and the cognitive composite score.
2.3. MRI acquisition and image analysis
2.3.1. Scan protocol
At each site, patients were scanned according to the routine MRI
protocol. Scanners and protocols at different sites varied but all
scanning was performed at 1.0 or 1.5 Tesla (Supplementary
Appendix 1). All scans included a 3-dimensional T1-weighted
gradient echo sequence and a fast ﬂuid-attenuated inversion
recovery sequence.
2.3.2. MRI measurements
MTL atrophy was assessed using manual measurement of the
hippocampus, automatically measured hippocampal volume using
multi-atlas segmentation (LEAP), volumetric measurement of the
expansion of the lateral ventricle, and a qualitative rating. All
volumetric measurements were corrected for intracranial volume
(ICV). The LEAP measurement was ICV-corrected by means of
a scaling factor from Montreal Neurological Institute (MNI), the
manual hippocampal measurement and the lateral ventricle
measurement were ICV-corrected by means of a scaling factor
derived from FSL software (FMRIB, Oxford, UK). The total rating
time of each method can be found in Supplementary Table 1. Rater
time needed for analysis was lowest for LEAP hippocampal
measurement (4 minutes) followed by the qualitative rating (5
minutes). Rater time was 30 minutes for lateral ventricle
measurement and 150minutes for manual hippocampal volumetry.
For the manual segmentation of the hippocampus, the baseline
3-dimensional T1-weighted volume sequence was reformatted in
2-mm slices (in-plane resolution: 1  1 mm) and oriented perpen-
dicular to the long axis of the left hippocampus (van de Pol et al.,
2007a). Regions of interest (ROIs) of the hippocampus were con-
structed by manual delineation of hippocampal borders on both
sides on the reformatted slices, using the software package devel-
oped in-house, Show_Images 3.7.0 (VU University Medical Center,
Amsterdam, the Netherlands). Delineation of the hippocampus was
performed using previously described criteria (Jack, 1994; van de Pol
et al., 2007a, 2009) by 3 trained technicians (coefﬁcients of variation:
interrater <8%, intrarater <5%) blinded to diagnosis. ROIs included
the dentate gyrus, cornu ammonis, subiculum, ﬁmbria, and alveus.
Baseline hippocampal volume was calculated by multiplying the
total area of all ROIs of each hippocampus by slice thickness. Baseline
hippocampal volumes were adjusted for ICV, using the scaling factor
derived from SIENAX (part of FSL; FMRIB) (Sluimer et al., 2008).
Automated hippocampal volumetry was performed using the
LEAP method (Wolz et al., 2010a; Supplementary Fig. 1). In this
method, multi-atlas registration is applied to a cohort of brain
images after representing the whole population together with an
initial set of atlases. The initial set is propagated to a number of
unlabeled images in their local neighborhoodwhich are used to label
them. Images labeled in this way become atlases themselves and are,
consequently, further propagated throughout the whole data set. In
this way, each image is labeled using a number of atlases in its close
vicinity, which has been shown to performmore robustly on diverse
data sets than other multi-atlas registration techniques (Wolz et al.,
2010a). A brief visual inspection of the segmented hippocampi was
performed to identify clear failures of the automatedmethod. Except
for technical failures listed below (see 4.3. Technical considerations),no subjects were excluded after this inspection and no manual
correction was performed.
Measurement of the lateral ventricle was executed with an
extension of SIENAX (Smith et al., 2001, 2002), part of FSL (FMRIB)
(Smith et al., 2004). SIENAX starts by extracting brain and skull
images from the single whole-head input data (Smith, 2002). The
brain image is then afﬁne-registered to MNI152 space (Jenkinson
and Smith, 2001; Jenkinson et al., 2002) using the skull image to
determine the registration scaling. This is primarily to obtain the
volumetric scaling factor, to be used as a normalization for head
size. Next, tissue-type segmentation is carried out (Zhang et al.,
2001) to calculate total volume of brain tissue (including separate
estimates of volumes of gray matter, white matter, peripheral gray
matter, and ventricular CSF). After the tissue segmentation,
a registered mask is used to exclude the CSF on the outer side of the
brain. The resulting ventricular structure is manually edited when
the segmentation or the mask did not take the whole ventricle into
account or contained CSF pixels not belonging to the ventricles (CSF
found outside the ventricles).
The visual rating of MTL atrophy was performed using a quali-
tative scale (Scheltens et al., 1992). Rating was performed on
coronal T1-weighted images using a 5-point visual scale (MTA-
scores), ranging from 0 (no atrophy) to 4 (severe atrophy) based on
the height of the hippocampal formation and the surrounding CSF
spaces. In the analysis, the sum of both sides (left and right) was
used. All visual rating was performed at VUmc by a number of
trained raters. Scans from VUmc were rated by a group of 3 raters
supervised by a neuroradiologist (intrarater weighted Cohen k >
0.80; interrater weighted Cohen k > 0.80) (Henneman et al., 2009).
The DESCRIPA scans were rated by a single rater from VUmc
(intrarater weighted Cohen k ¼ 0.68) (van de Pol et al., 2009).
2.4. CSF analyses
CSF was collected by lumbar puncture and levels of beta amyloid
(Ab)1e42, total tau (t-tau), and phosphorylated tau (p-tau) in CSF
were measured using commercially available sandwich enzyme-
linked immunosorbent assays (Innotest b-amyloid 1-42; Innotest
hTAU-Ag; Innogenetics, Ghent, Belgium), specially constructed to
measure Ab1e42 and t-tau (Andreasen et al., 1999; Blennow et al.,
1995) by experienced technicians at the lab in Gothenburg for the
DESCRIPA cohort and in Amsterdam for the VUmc cohort. CSF was
available for 147 subjects.We corrected for interlaboratory enzyme-
linked immunosorbent assay differences by analyzing 33 samples
at both labs and we adjusted VUmc values to those of DESCRIPA
using the following equating formula: Gothenborg ¼ average
Gothenborg þ (SD Gothenborg/SD VUmc)  (VUmc  average
VUmc) (Kolen and Brennan, 1995). Abnormal values for CSF
measureswere a concentration550 pg/mL for Ab1e42,>52 pg/mL
for p-tau, and >375 pg/mL for t-tau (Mulder et al., 2010).
2.5. APOE genotype
APOE genotype was determined by polymerase chain reaction of
genomic DNA extracted from ethylenediaminetetraacetic acid
(EDTA)–anticoagulated blood in 262 subjects. Subjects were clas-
siﬁed as APOE-ε4 carriers or noncarriers.
2.6. Statistical analysis
Statistical analysis was performed with IBM SPSS version 19
(Chicago, IL, USA) and the statistical software package R (R Foun-
dation, Vienna, Austria). Correlations between the different
methods for MTL assessment and between MTL and other bio-
markes (CSF, APOE-e4 allele) were analyzed by the Pearson
Table 1
Subject characteristics
DESCRIPA
cohort
VUmc
cohort
Combined
cohort
n 156 172 328
Age, y 70.3 (7.9) 70.9 (7.3) 70.6 (7.6)
Female (%) 59.6 44.2a 51.5
Education, y 8.5 (3.9) 11.2 (3.3)b 10 (3.8)
MMSE score 27.2 (2.3) 26.6 (2.6)c 27.0 (2.5)
Z-score word list
(delayed recall)
1.23 (1.20) 1.58 (1.10)c 1.38 (1.20)
ApoE-e4 carrier (%) 45 56 51
Homo/heterozygous ApoE-e4
carriers (%)
38/7 38/18 38/13
Manual hippocampus (mm3) 7874 (1294) 7462 (1097)a 7657 (1211)
LEAP hippocampus (mm3) 5897 (798) 5446 (632)b 5661 (749)
MTA-score 2.8 (1.7) 2.3 (1.7)a 2.5 (1.7)
Lateral ventricle (mm3) 53,409
(26,105)
57,374
(28,042)
55,488
(27,170)
CSF Ab1e42 (pg/mL) 561 (256) 604 (283) 594 (277)
Abnormal CSF Ab1e42 (%) 49 52 51
CSF t-tau (pg/mL) 418 (298) 558 (347)c 525 (351)
Abnormal CSF t-tau (%) 51 68 64
CSF p-tau (pg/mL) 64 (33) 80 (47) 77 (45)
Abnormal CSF p-tau (%) 54 71 67
CSF ratio Ab1e42:t-tau 2.2 (2.2) 1.6 (1.5) 1.8 (1.6)
Outcome at last FU (%)
No AD 80.8 64.5 72.0
AD 19.2 35.5b 28.0
Average FU nondemented
subjects (y)
2.35 (0.84) 2.67 (1.31)c 2.47 (1.09)
Average time to AD (y) 1.51 (0.71) 2.29 (1.39)a 2.07 (1.28)
All volumetric measurements are corrected for intracranial volume. Values aremean
(SD).
Key: Ab1e42, beta amyloid 1e42; AD, Alzheimer’s disease; ApoE, apolipoprotein E
genotype; CSF, cerebrospinal ﬂuid; FU, follow-up; LEAP, learning embeddings for
atlas propagation; MMSE, Mini Mental State Examination; MTA-score, qualitative
ratings of medial temporal lobe atrophy; p-tau, phosphorylated tau; t-tau, total tau.
a p < 0.01 for differences between cohorts.
b p < 0.001 for differences between cohorts.
c p < 0.05 for differences between cohorts.
Table 2
Correlation with CSF measurements
Ab1e42 T-tau P-tau Ab/T-tau
Manual hippocampus 0.09 0.28a 0.23a 0.29a
LEAP hippocampus 0.05 0.32a 0.27a 0.33a
MTA-score 0.20b 0.11 0.06 0.24a
Lateral ventricle 0.30a 0.12 0.16b 0.10
Shown are Pearson correlation coefﬁcients or Spearman-rank correlation coefﬁ-
cients (correlations with MTA-score).
Key: Ab, beta amyloid; CSF, cerebrospinal ﬂuid; LEAP, learning embeddings for atlas
propagation; MTA-score, qualitative ratings of medial temporal lobe atrophy; P-tau,
phosphorylated tau; T-tau, total tau.
a p < 0.01.
b p < 0.05.
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test for correlations including the MTA-score. Intraclass correlation
coefﬁcient (ICC) and paired t test were performed to investigate the
agreement between MTL measurements.
The main outcome measure was the area under the curve (AUC)
for AD-type dementia after 2 years of follow-up, calculated using
a time-dependent receiver operating characteristics curve in R
(Heagerty et al., 2000). Differences in AUC between methods were
tested as described elsewhere (Hanley and McNeil, 1983). We
calculated the sensitivity, speciﬁcity, positive predictive value,
negative predictive value, odds ratio (OR), and hazard ratio (HR) for
AD-type dementia at the 2-year follow-up using data-driven cut
points based on a time-dependent receiver operating characteris-
tics analysis. First we calculated the cut point that maximized the
Youden Index (sensitivity þ speciﬁcity  1) for predicting AD-type
dementia after 2 years. Second, we selected cut points that pre-
dicted AD-type dementia with a sensitivity of 85%. Cut points were
calculated in the whole sample and in each cohort separately.
Spline analyses were performed to determine AD-free survival after
2 years as a function of each MRI measurement in the total cohort.
Slope analyses with mixed models were performed to investigate
whether MTL atrophy was associated with change on the MMSE
and a cognitive composite score at follow-up. The analyses included
the baseline score and available follow-up scores up to 5 years after
baseline andwere corrected for age and education. An unstructured
covariance structure with center as a random effect was used
because this model provided the best 2 log likelihood compared
withmodels with simpler covariance structures (Visser et al., 2009).
3. Results
3.1. Subject characteristics
From the total group of MCI patients included in this study 37%
were diagnosed as nonamnestic MCI (73% single-domain and 27%
multi-domain) and 63% amnestic MCI (44% single-domain and 56%
multi-domain). Baseline and follow-up characteristics are shown in
Table 1. Both cohorts were comparable for age and APOE-e4 status.
The DESCRIPA cohort included more female participants and
education was lower compared with the VUmc cohort. Scores on
the MMSE and delayed recall task were lower in the VUmc cohort.
At follow-up, 91 subjects were diagnosed with probable Alzheimer-
type dementia (28%). Conversion rate was higher in the VUmc
cohort (35.5%) than in the DESCRIPA cohort (19.2%), p < 0.001.
Twelve subjects converted to a different type of dementia at follow-
up: 4 subjects converted to frontotemporal dementia, 6 to dementia
with Lewy bodies, 1 to vascular dementia, and 1 to another form of
dementia. These subjects were included in the no-AD group. The
follow-up length was slightly longer in the VUmc cohort. Charac-
teristics of subjects with and without AD-type dementia at follow-
up in each cohort are shown in Supplementary Table 2.
3.2. Correlations between MTL measures
Manual and automated LEAP hippocampal volumes correlated
highly (Pearson r ¼ 0.71; p < 0.001) with intermediate agreement
(ICC, 0.38; p < 0.001, BlandeAltman plot; Supplementary Fig. 2).
The 2 techniques were signiﬁcantly different using the paired t test
(t ¼ 42.27; p < 0.01) with the LEAP hippocampal measurement
showing lower volumes. Using the cut point based on the Youden
index, the k and the overlap between manual and LEAP hippo-
campal volume were 0.60 and 0.80 respectively.
The correlation between theMTA-score and themanual and LEAP
hippocampal volume was 0.36 and 0.27 respectively (p < 0.01).
Using the cut point based on the Youden index, the kwas0.29 and theoverlap between scores 0.69 for manual versus MTA-score and 0.37
(k) and0.65 (overlap) for LEAPversusMTA-score. The lateral ventricle
measurement strongly correlated with MTA-score (r ¼ 0.60;
p < 0.001) and showed weak correlations with manual (r ¼ 0.20;
p < 0.01) and LEAP hippocampal volume (r ¼ 0.20; p < 0.01).
3.3. Correlations with AD biomarkers
Manual and LEAP hippocampal volume signiﬁcantly correlated
with CSF t-tau, p-tau, and Ab/t-tau ratio (all p < 0.01; Table 2). The
MTA-score correlatedwith Ab1e42 (p< 0.05) and the ratio Ab/t-tau
(p< 0.01). The lateral ventricle volume correlatedwith Ab1e42 (p<
0.01) and p-tau (p < 0.05). Only the LEAP hippocampal volume at
baseline was associated with APOE-e4 allele status (LEAP volume
Fig. 1. AUC of a ROC-curve for MRI measurements for (A) total sample, (B) DESCRIPA
cohort and (C) VUmc cohort. All volumetric measurements are corrected for intra-
cranial volume. Abbreviations: AUC, area under the curve; LEAP, learning embeddings
for atlas propagation; MRI, magnetic resonance imaging; MTA, medial temporal lobe
atrophy; ROC, receiver operating characteristics.
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noncarriers; t ¼ 2.72; p < 0.001).
3.4. Predictors of AD-type dementia in the combined sample
In the total sample, the AUC for prediction of AD-type dementia
at the 2-year follow-up was highest for the LEAP hippocampal
measurement (0.71) andmanual hippocampalmeasurement (0.71),
and it was substantially lower for the MTA-score (0.65) and lateral
ventricle (0.60) (Fig. 1). If measurements were dichotomized using
the cut point that maximized the Youden index, the overall
predictive accuracy for AD after 2 years was best for themanual and
LEAP hippocampal volumetric measurements (OR, 6.4e6.5; HR,
4.4e4.5), and lowest for the qualitative rating and lateral ventricle
volume (OR,<4; HR,<3) (Table 3). Fig. 2 shows the 2-year dementia
risk according to baseline MTL score based on spline analysis. The
x-axis shows the degree of atrophy and the y-axis depicts the risk
for AD at follow-up associated with the degree of atrophy. Manual
and LEAP hippocampal volume had a nonlinear relation with
dementia risk indicating that the risk for dementia did not change
much with very large or very small volumes. The optimal cut point
based on the Youden index for these measures was found halfway
through the linear part of the plot.
If measurements were dichotomized using the cut point that
provided a sensitivity of 85% similar results were obtained. These
analyses also showed that the speciﬁcity was higher for manual and
LEAP volumetric measurements of hippocampal volume than for
MTA-score and lateral ventricle volume.
3.5. Predictors of cognitive decline
Because subjects with MCI might convert to AD-type dementia
after the 2-year follow-up, we performed slope analyses with
annual cognitive decline up to 5 years as an outcome measure.
Subjects with abnormal scores for manual and LEAP hippocampal
measurement andMTA-score at baseline declined 2 times as fast on
the MMSE (p < 0.001) and declined 2.6e4 times as fast on the
cognitive composite score (p < 0.01) compared with subjects with
normal MTL scores (Table 4, Fig. 3). The lateral ventricle volume
only predicted decline on the cognitive composite score (p < 0.01)
(Table 4, Fig. 3).
3.6. Multicenter versus single-center cohort
In the DESCRIPA multicenter cohort, AUC analysis showed best
predictive accuracy values for LEAP (0.74) followed by manual
hippocampus volume (0.71). In the single-center cohort, manual
hippocampus was the best predictor for AD (AUC ¼ 0.69) followed
by LEAP (AUC ¼ 0.68) and MTA-score (AUC ¼ 0.65) (Fig. 1). To
investigate whether optimal cut points for predicting AD-type
dementia differed between the multicenter and single center
cohort, we calculated within each cohort the cut point that maxi-
mized the Youden index and the cut point that provided a sensi-
tivity of 85% for the prediction of AD-type dementia after 2 year
(Supplementary Table 3). These analyses showed that the optimal
cut points for the manual and LEAP hippocampal measurement
were similar between the multicenter and the single-center cohort
with relative differences of less than 2.5% for the cut points based
on the Youden index and less than 5.5% for the cut points that
provided a sensitivity of 85%.
4. Discussion
The present study showed that volumetric measurements of the
MTL are better predictors for AD-type dementia in subjects withMCI than a qualitative rating or the assessment of the lateral
ventricle volume.
This is to our knowledge the ﬁrst study comparing 4 different
measures for MTL atrophy in a large sample of MCI subjects from
a memory clinic population. Furthermore this is the ﬁrst study
to compare the predictive accuracy of these measurements in
single-center and multicenter settings and to investigate the cor-
relations between these measurements and other AD biomarkers.
Table 3
Predictive accuracy for Alzheimer-type dementia after 2 years
Cutoff Sens Spec PPV NPV OR HR
Cut point based on Youden
index
Manual hippocampus 7559 0.78 0.65 0.46 0.88 6.47 4.55
LEAP hippocampus 5374 0.66 0.77 0.52 0.85 6.40 4.43
MTA-score 3 0.66 0.64 0.41 0.83 3.40 2.77
Lateral ventricle 58,491 0.53 0.68 0.39 0.79 2.36 2.01
Cut point for a sensitivity
of 85%
Manual hippocampus 8379 0.88 0.37 0.35 0.89 4.22 3.15
LEAP hippocampus 5901 0.87 0.42 0.36 0.89 4.72 3.34
MTA-score 2 0.86 0.30 0.32 0.85 2.57 2.03
Lateral ventricle 34,859 0.84 0.27 0.31 0.81 1.87 2.00
All volumetric measurements are corrected for intracranial volume. Cutoff in mm3
for volumetric measurements.
Key: HR, hazard ratio; LEAP, learning embeddings for atlas propagation; MTA-score,
qualitative ratings of medial temporal lobe atrophy; NPV, negative predictive value;
OR, odds ratio; PPV, positive predictive value; Sens, sensitivity; Spec, speciﬁcity.
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4.1.1. Predictive accuracy
The degree of neurodegeneration in MTL structures is the best
MRI marker of imminent conversion to AD, with decreased
hippocampal volume being the most robust structural MRI feature
(Risacher et al., 2009). In our study, predictive accuracy of both
volumetric hippocampal measurements for AD-type dementia wasFig. 2. Spline analyses showing AD-free survival after 2 years as function of MRI measure
volume, (C) MTA-score, and (D) lateral ventricle volume. Red line indicates cut point that m
volume. Abbreviations: AD, Alzheimer’s disease; LEAP, learning embeddings for atlas propa
score, qualitative ratings of medial temporal lobe atrophy.indeed higher than that of the qualitative rating and lateral
ventricle measure. This is in line with current evidence stating that
manual and automated volumetric methods show similar perfor-
mance in diagnosing AD (Colliot et al., 2008; Hsu et al., 2002;
Lehmann et al., 2010; Sanchez-Benavides et al., 2010a) and that
qualitative rating scales or lateral ventricle measurements are less
accurate predictors than volumetric methods (Ridha et al., 2007;
Urs et al., 2009; Westman et al., 2011).
The slope analyses of cognitive decline over 5 years again yielded
similar results with LEAP and manual hippocampal volume at
baseline predicting cognitive decline on the MMSE and a cognitive
composite score. Slope analysis for the MTA-score predicted cogni-
tive decline equallywell as the volumetric measures. This is again in
line with previous ﬁndings showing that automatically measured
volume change in the hippocampus is correlated with decline of
performance on the MMSE (Arlt et al., 2012) and that manually
measured hippocampal volume reduction is correlated with the
severity of impairment on neuropsychological tests (Yavuz et al.,
2007). Another study found that performance on the MMSE was
directly correlated with hippocampal volume (Laakso et al., 1995).
4.1.2. Relation with other AD biomarkers
Manual and LEAP hippocampal volume signiﬁcantly correlated
with CSF t-tau and p-tau but not with Ab1e42. The correlation of
hippocampal volumetric measurements with CSF tau but not with
CSF Ab is in line with previous studies conducted in subjects with
MCI (Apostolova et al., 2010; Carmichael et al., 2012) and subjects
with prodromal AD or AD (de Souza et al., 2012). It might bement in the total cohort for (A) manual hippocampal volume, (B) LEAP hippocampal
aximized the Youden index. All volumetric measurements are corrected for intracranial
gation; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; MTA-
Table 4
Annual cognitive decline over 5 years of follow-up
MMSE score Cognitive composite score
Baseline
score
Slope Baseline
score
Slope
Manual
hippocampus
Normal 27.6 (0.47)a 0.45 (0.09)a,b 0.90 (0.08) 0.05 (0.02)c,d
Abnormal 26.7 (0.47) 1.04 (0.10)e 1.00 (0.09) 0.17 (0.03)e
LEAP
hippocampus
Normal 27.4 (0.42)c 0.54 (0.09)a,b 0.92 (0.07) 0.07 (0.02)b,c
Abnormal 26.5 (0.46) 1.13 (0.12)e 1.01 (0.09) 0.18 (0.04)e
MTA-score
Normal 27.4 (0.43)f 0.49 (0.08)a,e 0.84 (0.07)c 0.05 (0.02)a,b
Abnormal 26.9 (0.43) 1.14 (0.11)e 1.05 (0.08) 0.20 (0.03)e
Lateral ventricle
Normal 27.4 (0.46) 0.70 (0.09)e 0.96 (0.07) 0.01 (0.03)c
Abnormal 27.0 (0.48) 0.94 (0.13)e 1.00 (0.09) 0.22 (0.05)c,e
Data are mean (SD). Slope refers to annual change on the test. A negative slope
indicates cognitive decline. Scores dichotomized based on Youden cutoffs.
Key: LEAP, learning embeddings for atlas propagation; MMSE, Mini Mental State
Examination; MTA-score, qualitative ratings of medial temporal lobe atrophy.
a p < 0.001 for baseline score or slope compared with baseline score or slope in
the abnormal biomarker group.
b p < 0.01 for slope different from 0 (this means a statistically signiﬁcant change
over time in test score).
c p < 0.01 for baseline score or slope compared with baseline score or slope in the
abnormal biomarker group.
d p < 0.05 for slope different from 0 (this means a statistically signiﬁcant change
over time in test score).
e p < 0.001 for slope different from 0 (this means a statistically signiﬁcant change
over time in test score).
f p < 0.05 for baseline score or slope compared with baseline score or slope in the
abnormal biomarker group.
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signiﬁcantly correlatedwith the density of neuroﬁbrillary tangles at
autopsy (Csernansky et al., 2004; Jack et al., 2002) but not with Ab
plaque load (Csernanskyet al., 2004). The qualitativeMTA-score and
lateral ventricle volume correlated with CSF Ab1e42. This correla-
tion might indicate that these MTL measures in part reﬂect gener-
alized brain atrophy because previous studies showed that lower
Ab1e42 levels but not t-tau levels were associated with total brain
atrophy and ventricular volume (Wahlund and Blennow, 2003).
4.1.3. Overlap between measurements
Although the LEAP and manual hippocampal measurement
correlated highly (r ¼ 0.71) and scores showed 80% overlap, the ICC
of 0.38 indicated a moderate agreement. This might be because the
LEAP volumewas consistently lower, because the ICC is sensitive for
absolute sizes. A previous study that compared LEAP with manual
measurements found a much higher ICC of 0.89 (Wolz et al., 2010a).
Although in this study volume obtained using LEAP was system-
atically lower than volumes obtained using the manual volumetric
measurement, this difference was smaller than in our study.
Differences in absolute volumes might be because of the use of
different borders for hippocampal delineation. Major parts of
the hippocampus are included in both volumetric methodswith the
only difference being that the LEAP method misses some of the
hippocampal head, some of the alveus, and some of the ﬁmbria, and
ends a few slices earlier than manual hippocampal outlining.
Despite the differences in raw volume, both methods have
a comparable diagnostic accuracy indicating that these parts are
less important for AD pathology. It is also likely that the cutoff
points for each hippocampal method likely reﬂected a similar
degree of abnormality. Namely, if we deﬁned the cutoff that
provided a sensitivity of 0.85, the speciﬁcity of each method was
equal. When the cutoff was used that optimized the Youden index,small differences in sensitivity and speciﬁcity were found but the
combination of sensitivity and speciﬁcity expressed as odds ratio
was the same. Differences in absolute volumes between different
measurement protocols might be reduced in the future as efforts
are made toward the harmonization of an MRI segmentation
protocol for hippocampal delineation (Boccardi et al., 2011; Frisoni
and Jack, 2011). Because manual volumetry is used as the standard
against which automated segmentation algorithms are assessed,
future synchronization and comparison of both techniques will be
facilitated. Correlations between manual and LEAP volumetric
measurements and MTA-score were low with a moderate overlap
between both methods. The same pattern was found for correla-
tions and overlap between both volumetric hippocampal mea-
surements and expansion of the lateral ventricle.
Our ﬁndings indicate, in line with previous studies, that volu-
metric and qualitative measures of MTL atrophy measure different
aspects of AD pathology (Visser et al., 2002b; Wahlund et al., 1999).
Manual and LEAP hippocampal volume correlated with each other,
both showed high predictive accuracy values, and both correlated
with t-tau and p-tau but not with Ab1e42. In contrast, visually rated
MTA-score and expansion of the lateral ventricle correlated highly
with each other but notwith the volumetricmeasures. They showed
lower predictive accuracy for AD conversion than the volumetric
measures and correlated highly with Ab in CSF rather than CSF tau.
As already discussed in this report, it is possible that both the MTA-
score and lateral ventricle volume reﬂect a widening of ventricular
spaces (i.e., the temporal horn), which might be indicative of
generalized atrophy rather than atrophy of the hippocampus alone.
4.2. Comparison of cohorts
None of the MTL measures showed major differences in
predictive accuracy between the single and multicenter cohort.
When optimal cut points for each measure were calculated for each
cohort separately these cut points only slightly differed between
the cohorts for the volumetric hippocampal measurements, which
shows that volumetric measurements display stable cut points
across different cohorts. Some differences were noted between the
cohorts on cut points for the MTA-score and lateral ventricle, sug-
gesting that MTA-score and lateral ventricle are more sensitive for
cohort differences.
4.3. Technical considerations
In general automated measurements are more susceptible to
scanner and scan protocol variability. In our study, no signiﬁcant
differences between both methods were found with LEAP showing
similar or even slightly better performance than manual volumetry.
This suggests that automated measurements can be performed in
multicenter studies without strict standardization of scan protocols.
The percentage of technical failures was 0.07%manual hippocampal
measurement and 0.03% for LEAP hippocampal measurement. All
failures were observed in 2 DESCRIPA sites that apparently used
scan frequencies which occasionally led to technical errors during
the preprocessing phase (e.g., intensity problems), making these
particular scans unsuitable for applying subsequent volumetric
measurements. SIENAX-related measurements (ICV and lateral
ventricular volume) yielded a higher technical failure rate (1% for
lateral ventricle) and were observed across all sites. These were
because of calculation errors or a combination of software and
image quality problems. These ﬁndings indicate that the lateral
ventricle measurement is more sensitive for speciﬁc differences in
image quality than a manual or automated hippocampal
measurement. It should be noted than scan sequences were
designed for routine clinical practice and not for automated
Fig. 3. Slope analyses showing annual cognitive decline on (A) the MMSE and (B)
a cognitive composite score as predicted by baseline medial temporal lobe measure-
ments. Abnormal MRI values at baseline were deﬁned as manual hippocampal volume
<7559 mm3, LEAP hippocampal volume <5374 mm3, MTA-score 3, and lateral
ventricle volume 58491 mm3. The solid lines indicate the subjects with normal
values. The dotted lines indicates subjects with abnormal values. All volumetric
measurements are corrected for intracranial volume. The cognitive composite score ¼
average z-score of learning or delayed recall of a word list learning test or equivalent
memory test, the Trail Making Test part A, Trail Making Test part B, verbal ﬂuency, Rey
ﬁgure copy test, or an equivalent test. Abbreviations: LATVEN, lateral ventricle volume;
LEAP, learning embeddings for atlas propagation; MAN, manual hippocampal volume;
MMSE, Mini Mental State Examination; MRI, magnetic resonance imaging; MTA,
medial temporal lobe atrophy score; MTA-score, qualitative ratings of medial temporal
lobe atrophy.
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using protocols optimized for automated measurements.
4.4. Limitations
The present study had several limitations. There were differ-
ences in subject characteristics between the single-center and
multicenter cohort. Subjects from the single-center VUmc cohort
were more severely impaired and had lower baseline MMSE scores,
more severe memory impairment, a lower hippocampal volume,
higher CSF tau, and a higher conversion rate to dementia. Despite
these differences, however, the predictive accuracy was similar in
each cohort. Another limitation is that the cutoffs of all MRI
measurements were determined within a study population that
also included the subjects from the present analyses. This could
have led to an overestimation of the predictive accuracy. However,
it is unlikely that it inﬂuenced our ﬁndings with respect to the
differences in predictive accuracy between MRI measurements,
because we used the same method to deﬁne the cut point for each
measurement. Follow-up data with AD diagnosis for all subjects
was only available for a relatively short follow-up interval (2 years).
For clinical trials, however, short-term prognosis might be impor-
tant. For subjects inwhom long-term follow-up datawere available,predictive accuracy for annual cognitive decline up to 5 years was
additionally investigated. The diagnosis of AD at follow-up was not
validated neuropathologically which might have possibly led to the
misclassiﬁcation of some cases. We used scanners with different
ﬁeld strengths (1T and 1.5T) which reﬂected real-life situations in
which scanners and magnetic ﬁeld strengths vary. However, these
differences might have introduced bias. We therefore compared the
hippocampal volume between subjects scanned on a 1.0T scanner
(n ¼ 127) and a 1.5T scanner (n ¼ 201) after correction for age, sex,
educational level, baseline MMSE score, and follow-up diagnosis.
The difference in volume between 1.0T and 1.5T scanners was 0.2%
for the LEAP method (p ¼ 0.9; van Rossum et al., 2012), 0.9% for
manual hippocampal volume (p ¼ 0.6), and 1.5% for the lateral
ventricle volume (p ¼ 0.8). We also tested whether ﬁeld strength
modulated the effect of the volumetric measures on conversion to
AD-type dementia. For none of the measures the interaction
between ﬁeld strength and volumetric measure was statistically
signiﬁcantly associated with conversion (p > 0.15). A recent study
also found a limited effect of ﬁeld strength on hippocampal volume.
This study compared the hippocampal volume measured by the
LEAP method between subjects scanned both on a 1.5T and 3T
scanner and found a very high correlation between the measure-
ments on each scanner (r ¼ 0.98) (Wolz 2013, unpublished data).
The volumes measured on 3T were on average 24.4 mm3 or 1.17%
larger than on 1.5T (Wolz 2013, unpublished). This variability was
similar to that for volumes rescanned on scanners with the same
ﬁeld strength (1.5%) (Wolz 2013, unpublished). Taken together, it is
unlikely that the small difference in ﬁeld strength in our study had
a major effect on the volumetric measurements in our study.
Different methods were used for ICV correction of both hippo-
campal measurements (see section 2.3.2.). Both correction methods
were thoroughly compared and showed high correlations (ICC ¼
0.93 for LEAP with MNI vs. FSL scaling and 0.95 for manual volu-
metric measurement with MNI vs. FSL scaling) and similar results
regarding predictive accuracy. As a result of this analysis, ICV
correction of each individual method was applied. It can be
considered a strength that for this diagnostic study a population
from a memory clinic setting was used. A consequence however is
that these ﬁndings might not be applicable to other settings, in-
cluding the general population.
4.5. Clinical implications
Volumetric measurements of the MTL are the best predictors for
AD-type dementia in subjects with MCI. Both volumetric
measurements strongly correlate with CSF markers of neuronal
injury (CSF t-tau and p-tau), are able to predict cognitive decline,
and show consistent cutoff values between different cohorts. LEAP
hippocampal volume has the advantage over manual volumetry in
that it needs much less rater time and shows no interrater vari-
ability effects. In addition, LEAP has a low technical failure rate.
Visual rating scales are also quick and easy to perform but show
lower predictive accuracy rates and higher inter- and intra-
individual variability effects (DeCarli et al., 1990) compared with
LEAP volumetric measurement. Another disadvantage of visual
rating scales, although outside the scope of this study, is that they
cannot detect subtle atrophy progression and are thus insensitive to
change over time (Ridha et al., 2007; Urs et al., 2009). Because the
hippocampus is among the ﬁrst areas affected by the disease
(Chupin et al., 2009; Lötjönen et al., 2011), repeated measurement
of its volume is clinically important. LEAP hippocampal measure-
ment is suitable for implementation in clinical practice with on
average 4-minute control time on a standard computer. Cut points
that maximized the balance between sensitivity and speciﬁcity as
expressed by the Youden index or that provided a sensitivity of 85%
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preferred because it has shown to be more consistent between the
multi- and single-center cohort (Supplementary Table 3).
Depending on the clinical needs, other cut points can be chosen,
that for example maximize the positive or negative predictive value
(Bartlett et al., 2012).
Any choice for a speciﬁc cut point has a trade-off between the
chance of missing the disease (false negative rate, 1-sensitivity) or
incorrectly diagnosing someone as having the disease (false posi-
tive rate, 1-speciﬁcity). The choice will therefore depend on its
clinical use. For example, if a treatment for MCI caused by ADwould
be available the choice might depend on the safety proﬁle of the
treatment. If a treatment has many or severe side effects, high
speciﬁcity is more important than a high sensitivity and the
opposite is true for treatments with few side effects. If treatment is
not available and biomarkers are used for diagnosis, one might
prefer to use a cut point with a low false positive rate because an
incorrect diagnosis of AD might have a major negative effect on the
patient.
4.6. Future directions
Future MRI studies need to investigate abnormalities in AD
signature regions in and outside the MTL. A recent study found that
subjects with future cognitive impairment (preclinical AD and MCI)
also showed reduced brain volume in posterior cingulate and/or
precuneus and orbitofrontal cortex, at least 4 years before any
cognitive symptoms (Tondelli et al., 2012). Other structural MRI
studies also found abnormalities in AD or MCI outside the MTL
region such as the corpus callosum (Chen et al., 2009; Di Paola
et al., 2010; Serra et al., 2010; Wang and Su, 2006), cingulum
(Callen et al., 2001; Choo et al., 2010; Jones et al., 2006), parietal
(Jacobs et al., 2012), temporal lobe other thanMTL (Chincarini et al.,
2011), and frontal lobe (Burgmans et al., 2009). Future MRI studies
need to investigate abnormalities in AD signature regions in and
outside the MTL.
4.7. Conclusion
Volumetric hippocampal measurements are the best predictors
of conversion to AD-type dementia in subjects with MCI after
2-year follow-up and are able to predict annual cognitive decline.
Because of the limited rater time, LEAP automated hippocampal
measurement might be preferred.
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